Where to Buy Retatrutide

Where Can I Buy Retatrutide?

Retatrutide (LY3437943) is a triple-agonist investigational peptide developed by Eli Lilly that targets three metabolic receptors simultaneously: GLP-1, GIP, and GCGR (glucagon receptor). As of March 2026, retatrutide is in Phase 3 clinical trials under the TRIUMPH program and has not received regulatory approval from the FDA, EMA, or any other agency. For the latest on the approval timeline, see our retatrutide approval status tracker.

Because retatrutide is not an approved medication, it cannot be obtained through pharmacies, hospitals, or standard clinical channels. The only legitimate way to acquire retatrutide in 2026 is through research-grade peptide suppliers that provide the compound for in-vitro laboratory use. These suppliers synthesise retatrutide and verify purity through independent analytical laboratories.

Not all suppliers are equal. The research peptide market includes vendors with varying levels of quality control, transparency, and analytical rigour. The sections below cover exactly what to look for—and what to avoid—when evaluating where to buy retatrutide for research.

What Should I Look for When Buying Retatrutide?

The quality of research-grade retatrutide varies significantly across suppliers. Before purchasing, evaluate the following criteria to ensure the material meets analytical standards for reliable research.

HPLC Purity Verification

High-performance liquid chromatography (HPLC) is the gold standard for peptide purity analysis. Research-grade retatrutide should have an HPLC purity of 98% or higher. Remy Peptides’ retatrutide is verified at 99.262% purity (Batch RETP002) by Janoshik Analytical, an independent third-party laboratory widely regarded as the industry benchmark for peptide testing. The full Certificate of Analysis is published on our site.

Third-Party Certificate of Analysis (COA)

A legitimate COA should be batch-specific, issued by an independent laboratory (not the supplier’s in-house lab), and include HPLC chromatograms, mass spectrometry confirmation of molecular identity, and endotoxin testing results. Any supplier that cannot provide a verifiable, batch-specific COA from a named third-party lab should be treated with caution.

Proper Storage & Cold-Chain Shipping

Retatrutide is a peptide that degrades when exposed to heat, light, or repeated freeze-thaw cycles. Reputable suppliers ship with temperature-controlled packaging—insulated containers with cold packs or dry ice—to maintain the cold chain from production to delivery. Once received, retatrutide should be stored at 2–8°C (refrigerated) for active use or −20°C for long-term storage. Our peptide stability and storage guide covers optimal handling protocols in detail.

Retatrutide Pen vs Vial vs Raw Powder

Research-grade retatrutide is available in three primary formats. Each has distinct advantages depending on the research application, required dosing precision, and laboratory infrastructure.

The prefilled pen format eliminates reconstitution errors and provides the most reproducible dosing for protocols that require precise titration. Remy Peptides currently offers two pen formats: the Retatrutide 30mg Pen (300 clicks at 0.1mg/click) and the ProPeptide Retatrutide 20mg Pen (300 clicks at 15 clicks/mg). Vials are a cost-effective option for laboratories with established reconstitution workflows. Raw powder is primarily relevant for bulk procurement and custom formulation. For researchers comparing retatrutide to other compounds, see our retatrutide vs tirzepatide and retatrutide vs semaglutide analyses.

How Much Does Retatrutide Cost?

Research-grade retatrutide pricing depends on the format, purity, quantity, and supplier. As a pre-approval investigational compound, retatrutide is not covered by insurance and there is no “retail” price—only research supply pricing.

Current Market Pricing (March 2026)

Lyophilised vials (5–10mg) from research peptide vendors typically range from $150–$400 USD per vial, depending on purity and supplier reputation. Prices below $100 for a 10mg vial should be viewed with scepticism, as synthesis and third-party testing at scale are not cheap.

Remy Peptides offers the Retatrutide 30mg Pen with tiered research volume pricing:

• 1 pen: AED 1,200 (~$327 USD)
• 3-pack: AED 1,100/pen (~$300 USD/pen)
• 5-pack: AED 1,000/pen (~$272 USD/pen)

At 30mg per pen, this works out to approximately $9–$11 per milligram—competitive with or below most vial-format suppliers when factoring in the higher purity (99.262%) and the elimination of reconstitution waste. All orders include the Janoshik-verified COA and temperature-controlled shipping.

For institutional or bulk research procurement beyond the standard tiers, enquiries can be submitted via Telegram at @propeptide.

Red Flags to Avoid When Buying Retatrutide

The research peptide market is unregulated, which means quality varies enormously. The following red flags indicate a supplier that may be selling underdosed, contaminated, or counterfeit material.

• No third-party COA: If a supplier cannot provide a batch-specific Certificate of Analysis from a named, independent laboratory (not an in-house test), do not purchase. A legitimate COA includes HPLC chromatograms, mass spectrometry data, and the testing laboratory’s name and contact details.
• Suspiciously low prices: Retatrutide synthesis is complex and expensive. Prices significantly below market rate (e.g., under $100 for 10mg) often indicate underdosed or degraded product, substitution with cheaper peptides, or entirely fabricated COA documents.
• Oral capsule or tablet formats: Retatrutide is a peptide with a molecular weight of approximately 4,256 Da. Like all peptides, it is degraded by gastric enzymes when taken orally. Any supplier offering retatrutide in capsule or tablet form is selling an ineffective product. Legitimate retatrutide is supplied only in injectable formats (pens or vials) or as lyophilised powder.
• No batch number or lot tracking: Batch traceability is fundamental to quality control. If a supplier cannot tell you which batch you are receiving, there is no way to verify purity or provenance.
• Vague purity claims: Statements like “99% pure” without specifying the testing method (HPLC, LC-MS), the testing laboratory, or providing the actual chromatogram are insufficient. Demand specifics.
• No cold-chain shipping: Suppliers that ship peptides in standard packaging without temperature control are likely delivering degraded material, especially during summer months.

Is Retatrutide Legal to Buy?

Retatrutide is an investigational compound that has not been approved for clinical use in any country. Its legal status for research purchase varies by jurisdiction. Below is a summary of the regulatory landscape as of March 2026.

United States

Retatrutide is not a scheduled or controlled substance in the US. It can be legally purchased for research purposes under the classification of an unscheduled research chemical. It is not approved by the FDA for human or veterinary use. Suppliers label all retatrutide as “For Research Use Only” and buyers acknowledge this designation. Eli Lilly’s Phase 3 TRIUMPH trials are underway, with potential FDA submission anticipated in 2026–2027.

United Arab Emirates

Under UAE MoHAP Circular 17/2022, unapproved investigational compounds may be supplied for research purposes with appropriate labelling. Remy Peptides operates in compliance with this framework, with all materials clearly labelled for in-vitro laboratory research only. Retatrutide is available for research purchase in Dubai and across all emirates.

United Kingdom

Retatrutide is not a controlled substance under the Misuse of Drugs Act 1971 and is not regulated by the MHRA as a licensed medicine. It can be legally purchased as a research chemical in the UK. The MHRA would need to approve retatrutide through its own regulatory pathway before it could be prescribed clinically.

European Union

Retatrutide has no EMA marketing authorisation. Individual EU member states may have varying regulations on research chemical imports, but retatrutide is generally purchasable for laboratory research across the EU. Researchers should verify local customs and import requirements for peptide shipments.

Australia

Australia has the most restrictive framework for peptide research compounds. The Therapeutic Goods Administration (TGA) classifies injectable peptides under Schedule 4 (prescription-only medicines), and the October 2023 regulatory changes tightened personal importation rules. Researchers in Australia must work through authorised institutional channels or obtain appropriate permits for peptide imports. This makes Australia the most difficult market for individual researchers to source retatrutide.

How the Remy Peptides 30mg Pen Works

The Remy Peptides Retatrutide 30mg Pen is a prefilled FlexiPen designed for precise, reproducible dosing in research protocols. Each pen contains 30mg of retatrutide in a ready-to-use injectable solution, delivered across 300 clicks at 0.1mg per click.

Click-Based Dosing

The pen’s dial mechanism supports a maximum single administration of 60 clicks (6mg). This range is specifically designed to accommodate the published titration schedules from clinical trial protocols, which typically escalate from 0.5mg to 12mg over several months. Researchers can dial precise amounts without the volumetric measurement uncertainty associated with syringe-and-vial setups. Our retatrutide dosage and titration guide maps the click-based dosing to published Phase 2 and Phase 3 protocols.

Purity & Verification

Every Remy Peptides pen is produced from Batch RETP002, independently verified by Janoshik Analytical at 99.262% HPLC purity. The full Certificate of Analysis—including HPLC chromatograms and mass spectrometry data—is published and publicly accessible. Janoshik Analytical is the most widely referenced independent testing laboratory in the research peptide space, providing an additional layer of verification that in-house testing cannot match.

Compatibility with Titration Protocols

The 30mg total content per pen provides sufficient material for a complete titration escalation as described in published retatrutide trial data. At the standard maintenance dose ranges studied in the TRIUMPH program (up to 12mg weekly), a single pen supports multiple weeks of research protocol execution. For information on the safety profile observed during titration, see our retatrutide side effects analysis.